Home » AbbVie’s Viekira XR Gets Green Light From FDA
AbbVie’s Viekira XR Gets Green Light From FDA
The FDA has granted approval to AbbVie’s Viekira XR, which is for patients with hepatitis C virus.
The three-pill antiviral treatment was approved after Phase 3 studies showed 100 percent sustained virologic response 12 weeks after treatment in hepatitis C patients with chronic genotype 1.
The extended release tablets contain the following four active ingredients: ombitasvir, paritaprevir, ritonavir tablets and dasabuvir.
Upcoming Events
-
07May
-
14May
-
30May